GlobeNewswire by notified

Board of Directors of Evli Plc decided to establish a new share-based incentive plan

Share

EVLI PLC’S STOCK EXCHANGE RELEASE ON MARCH 7, 2023, AT 5:45 PM (EET/EEST)

The Board of Directors of Evli Plc has decided to establish a new share-based incentive plan for selected key employees of the group. The purpose of the plan is to align the interests of the company’s owners and key employees in order to increase the company’s value in the long term, to commit key employees to implement the company's strategy, objectives and long-term interest, and to offer them a competitive incentive plan based on earning Evli Plc’s shares. The plan is directed to Evli Ab's personnel to the extent decided by the Board.

The plan consists of one performance period from January 1, 2023 to June 30, 2026.

In the plan, the target group has the opportunity to earn Evli Plc’s series B shares based on performance.

The potential rewards from the performance period are based on the annualised fund revenue from new investments in Sweden. The value of the rewards to be paid from the performance period corresponds to a maximum total of 100,000 series B shares of Evli Plc, including also the proportion to be paid in cash. The target group of the performance period consists of 5 key employees.

The potential reward will be paid partly in Evli Plc’s series B shares and partly in cash. The cash proportion of the reward is intended to cover taxes and statutory social security contributions arising from the reward to the key employee. As a rule, no reward will be paid if the key employee's employment or director contract terminates before the reward payment.


EVLI PLC
Board of Directors


Additional information:
Maunu Lehtimäki, CEO, Evli Plc, tel. +358 50 553 3000, maunu.lehtimaki@evli.com


Evli Plc

We see wealth as an engine to drive progress. We draw on our heritage, broad expertise and Nordic values to grow and manage wealth for institutions, corporations and private persons in a responsible way.

We are the leading asset manager in Finland* offering a broad range of services including mutual funds, asset management and capital markets services, alternative investment products, equity research, share plan design and administration as well as Corporate Finance services. Responsible investing is integrated in every investment decision and our expertise is widely acknowledged by our clients. Evli has Finland's best expertise in responsible investment**.

Evli Group employs around 300 professionals and Evli has a total of EUR 16.0 billion in client assets under management (net 12/2022). Evli Plc’s B shares are listed on Nasdaq Helsinki Ltd.

* Kantar ProsperaExternal Asset Management Finland 2015, 2016, 2017, 2018, 2019, 2021, Kantar Prospera Private Banking 2019, 2020 Finland
** SFR Scandinavian Financial Research Institutional Investment Services Finland 2021, 2022

Distribution: Nasdaq Helsinki, main media, www.evli.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

TRESU Investment Holding A/S – Registration for investor call28.3.2023 11:04:29 CEST | Press release

TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 02.2023 28.03.2022 TRESU Investment Holding A/S is pleased to invite you to the financial results call, which is being held: Wednesday, 5 April 2022, at 11am CET. The Annual Report will be presented by Christian Jacob Flarup, CEO and Torben Børsting, CFO. After the presentation there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 4 April 2023 9am CET - fho@tresu.com Christian Jacob Flarup CEO, TRESU For further details, please contact: CEO, Christian Jacob Flarup, phone: +45 2027 7971 CFO, Torben Børsting, phone: +45 5130 2780 Attachment Quarterly reporting - Call - 2022 Q4

Alvotech Provides Update on Corporate Sustainability Framework28.3.2023 11:00:00 CEST | Press release

Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech. Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal. Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters. Alvotech’s corporate headquarters, purpose-built manuf

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release

Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose

Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse

Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor

Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse

NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5